Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies

Yakugaku Zasshi

Volumn 128, Issue 10, 2008, Pages 1449-1457

  Fujita, Yukiyoshi ^a   Yamamoto, Koujirou ^a,b   Aomori, Tohru ^a,b   Murakami, Hirokazu ^c   Horiuchi, Ryuya ^a,b  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Adverse effect; Bioequivalence; Dissolution test; Pharmacokinetics; Thalidomide

Indexed keywords

THALIDOMIDE;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG SOLUBILITY; HUMAN; MULTIPLE MYELOMA; PLASMA CONCENTRATION-TIME CURVE;

ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; FEMALE; GREAT BRITAIN; HUMANS; JAPAN; MALE; MEXICO; MIDDLE AGED; SOLUBILITY; THALIDOMIDE; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 53249123192     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.1449     Document Type: Article

References (15)

1. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., Barlogie B., N. Engl. J. Med., 341, 1565-1571 (1999).
2. Reepmeyer J. C., Cox D. C., J. AOAC Int., 80, 767-773 (1997).
3. Teo S. K., Colburn W. A., Thomas S. D., J. Clin. Pharmacol., 39, 1162-1168 (1999).
4. Teo S. K., Scheffler M. R., Kook K. A., Tracewell W. G., Colburn W. A., Stirling D. I., Thomas S. D., Biopharm. Drug Dispos., 21, 33-40 (2000).
5. Teo S. K., Colburn W. A., Tracewell W. G., Kook K. A., Stirling D. I., Jaworsky M. S., Scheffler M. A., Thomas S. D., Clin. Pharmacokinet., 43, 311-327 (2004).
6. Kamikawa R., Ikawa K., Morikawa N., Asaoku H., Iwato K., Sasaki A., Biol. Pharm. Bull., 29, 2331-2334 (2006).
7. Eriksson T., Bjorkman S., Fyge A., Ekberg H., J. Chromatogr., 582, 211-216 (1992).
8. Eriksson T., Bjorkman S., Clin. Chem., 43, 1094-1096 (1997).
9. Figg W. D., Raje S., Bauer K. S., Tompkins A., Venzon D., Bergan R., Chen A., Hamilton M., Pluda J., Reed E., J. Pharm. Sci., 88, 121-125 (1999).
10. Noormohamed F. H., Youle M. S., Higgs C. J., Kook K. A., Hawkins D. A., Lant A. F., Thomas S. D., AIDS Res. Hum. Retroviruses, 15, 1047-1052 (1999).
11. Tanigawara Y., Yamaoka K., Nakagawa T., Uno T., J. Pharm. Sci., 71, 1129-1133 (1982).
12. Kakimoto T., Hattori Y., Okamoto S., Sato N., Kamata T., Yamaguchi M., Morita K., Yamada T., Takayama N., Uchida H., Shimada N., Tanigawara Y., Ikeda Y., Jpn. J. Cancer Res., 93, 1029-1036 (2002).
13. Hattori Y., Kakimoto T., Okamoto S., Sato N., Ikeda Y., Int. J. Hematol., 79, 283-289 (2004).
14. Hattori Y., Iguchi T., Congenit. Anom., 44, 125-136 (2004).
15. Kodama T., Horiuchi R., Tsukamoto N., Nojima Y., Murakami H., Lab. Hematol., 10, 132-136 (2004).